Evidence map›Paper›PMID 40978008›Full record

ArticleInternational journal of pharmaceutics: X2025

The effects of recycling pharmaceutical formulations in laser powder bed fusion 3D printing - the influence of physical phenomena on printing performance.

Wessel Kooijman, Valerie R Levine, Robbert J Kok, Jonas Lindh, Julian Quodbach

Abstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wessel KooijmanDivision of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg, 99 3584, CG, Utrecht, the Netherlands.
Valerie R LevineDivision of Nanotechnology and Functional Materials, Department of Material Science and Engineering, Uppsala University, Uppsala SE-751 03, Box 35, Sweden.
Robbert J KokDivision of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg, 99 3584, CG, Utrecht, the Netherlands.
Jonas LindhDivision of Nanotechnology and Functional Materials, Department of Material Science and Engineering, Uppsala University, Uppsala SE-751 03, Box 35, Sweden.
Julian QuodbachDivision of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg, 99 3584, CG, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Laser powder bed fusion is an attractive technology for 3D printing objects in a powder bed and has been explored for printing pharmaceutical dosage forms, such as tablets. Recycling of non-sintered residual powder is not well understood, but is critical to prevent economic losses and improve the sustainability of this technique. We investigated the recyclability of three pharmaceutical formulations in the context of laser powder bed fusion of tablets. Three formulations consisting of common pharmaceutical polymers and the model drug indomethacin have been investigated up to ten print cycles. For each print cycle, powder and tablet samples were collected and analyzed for ageing phenomena. Results showed that polyvinyl alcohol and methacrylic acid-ethyl acrylate copolymer-based formulations were recyclable without changes in critical quality attributes of printed dosage forms for 5 and 9 cycles, respectively. A copovidone-based formulation showed a gradual increase in particle size over 10 cycles, resulting in a gradual decrease in tablet weight. This formulation was considered non-recyclable under the conditions evaluated in this work. The observed ageing phenomena were mainly related to changes in particle size, powder cohesion, and glass transition temperature. It is shown that considering powder ageing during formulation development is critical for optimal print performance and further development of laser powder bed fusion for pharmaceutical applications.

Indexed as

Laser powder bed fusionPersonalized medicinePowder ageingPowder recyclingSelective laser sinteringSolid oral dosage forms

Identifiers

PMID40978008
PMCPMC12446654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.